ライフサイエンスコーパス: hematocrit

1 ion increases EPO expression and the resting hematocrit.

2 easurements of blood and myocardium, and the hematocrit.

3 and matrix interference that increases with hematocrit.

4 ficant odds ratio of 1.123 for pre-operative hematocrit.

5 ed due to a hemodilution-induced decrease in hematocrit.

6 vessels less than 12-14 mum depending on the hematocrit.

7 ntake and positive effects on hemoglobin and hematocrit.

8 exposed animals, accompanied by elevation of hematocrit.

9 pirate in relation to the patient's baseline hematocrit.

10 levated EPO expression in bone and increased hematocrit.

11 or scrambled peptide treatment did not alter hematocrit.

12 ded body weight, white blood cell count, and hematocrit.

13 content of abdominal fat pads, and decreased hematocrit.

14 toration of EPO treatment are independent of hematocrit.

15 ameters with age adjusted for hemoglobin and hematocrit.

16 secutive daily doses significantly increased hematocrit.

17 classical erythropoietin receptor or affect hematocrit.

18 latelet adhesion varies greatly with the RBC hematocrit.

19 elation between the actual and the predicted hematocrit.

20 , averting a potentially detrimental fall in hematocrit.

21 mia with an increase in RBC, hemoglobin, and hematocrit.

22 gination at 10%, 20%, and 30% red blood cell hematocrit.

23 x (ABRI=number of blood units/(final-initial hematocrit+0.01)), with a cutoff value of 0.75.

24 8 compared with -0.13 +/- 1.0; P = 0.01) and hematocrit (1.04 +/- 2.2 compared with -0.15 +/- 2.4; P

25 s with severe (hematocrit, < 21%), moderate (hematocrit, 21-30%), and mild (hematocrit, > 30%) anemia

26 tated Ringer's solution titrated to maintain hematocrit +/- 3% from baseline levels.

27 nthly ESA dose of 75,000 units or higher and hematocrit 33% or less for at least 3 consecutive months

28 t group) or less intensive treatment (target hematocrit, 45 to 50%) (high-hematocrit group).

29 R (DynEq-CMR), where ECV is quantified using hematocrit-adjusted myocardial and blood T1 values measu

30 ight/d) lowered hemoglobin concentration and hematocrit after 6 d compared with nonsupplemented/NaCl-

31 d data set with a baseline/discharge pair of hematocrit, albumin, or total protein values were includ

32 and indicators of disease severity (current hematocrit, albumin, total protein, aspartate aminotrans

33 For normal hematocrit and a capillary diameter of 6.75 mum, the pre

34 G6PD deficiency by analyzing vital signs and hematocrit and by asking screening questions about sympt

35 These may include low hematocrit and coagulation abnormalities.

36 apacity is shown to increase with increasing hematocrit and decrease with increasing capillary diamet

37 ent response at baseline, large increases in hematocrit and decreases in erythropoietin dosing were o

38 emic hemodilution effectively normalized the hematocrit and did not significantly affect the histolog

39 ry cortex, whereas there are large capillary hematocrit and erythrocyte flux differences.

40 ular bifurcations resulting in reductions in hematocrit and flow rate in the daughter and mother vess

41 s no association between vital parameters or hematocrit and G6PD deficiency.

42 There was no difference in mean hematocrit and hemoglobin between the 2 groups.

43 cyte maturation markers, erythrocyte counts, hematocrit and hemoglobin concentration were similar in

44 OPN knock-out male mice exhibit lower hematocrit and hemoglobin levels compared with their wil

45 nlike wild type mice that manifest decreased hematocrit and hemoglobin levels when fed a low-iron die

46 d V(MCA)/V(ICA) ratio, after controlling for hematocrit and hemoglobin.

47 Although EPO treatment increased hematocrit and improved glucose tolerance in male and fe

48 21 inhibitor led to significant increases in hematocrit and led to an increase in SMAD7 expression in

49 tion, prostate volume, sebum production, and hematocrit and lipid levels did not differ between group

50 tion, prostate volume, sebum production, and hematocrit and lipid levels.

51 assess the association between preoperative hematocrit and mortality, and the Youden J Index was use

52 we investigate the relationship between RBC hematocrit and platelet adhesion activity.

53 Hematocrit and prostate-specific antigen levels increase

54 r lung oxygen diffusing capacity in terms of hematocrit and pulmonary capillary diameter.

55 sphorus; and faster rate of decline of serum hematocrit and serum bicarbonate.

56 usly quantifying blood flow (velocity, flux, hematocrit and shear rate) in extended networks at singl

57 blood viscosity from its major determinants hematocrit and the level of fibrinogen and C-reactive pr

58 ients were stratified by postoperative nadir hematocrit and the presence of postoperative MI.

59 imated by using a validated formula based on hematocrit and total plasma proteins at baseline.

60 pomorphic Kit allele (W41/41) corrects their hematocrits and deficiencies in erythroid progenitor num

61 x revascularization, heart failure, smoking, hematocrit, and baseline platelet count, patients with a

62 bidity, rheology data (immunoglobulin level, hematocrit, and blood viscosity), clinical examination r

63 al cell viability, only transiently elevated hematocrit, and did not affect the magnitude of cerebral

64 Schistocytosis, a decrease in hematocrit, and elevated serum lactate dehydrogenase lev

65 n patients with unexplained edema, increased hematocrit, and hypotension.

66 ature, release of mast cell mediators and/or hematocrit, and lung weight as a measure of vascular per

67 decrease in red and white cells, hemoglobin, hematocrit, and platelets.

68 correlations between vascular resistance and hematocrit are observed in various vessels, also defying

69 , and SOCS2(-/-)/Apc(Min/+) mice and assayed hematocrit as an indirect marker of disease severity.

70 ing time in vessel trauma and red blood cell hematocrit as platelets move to a vessel wall.

71 betes, lower creatinine clearance, decreased hematocrit, aspirin therapy, and nonsteroidal anti-infla

72 mo of age; P < 0.001), higher hemoglobin and hematocrit at 12 mo of age, and a significantly greater

73 ersus 10%), higher platelet count, and lower hematocrit at admission in the control group.

74 EPO 2500 led to a significant increase of hematocrit at day 4.

75 s 12.7%, respectively; P = .18) or mean (SD) hematocrit at discharge (34.5% [6.3%] vs 33.4% [6.8%], r

76 ardiac surgery and had a nadir postoperative hematocrit between 20% and 30%.

77 that used larger ESA doses in patients with hematocrit between 33% and 35.9% had higher mortality ra

78 demographics, hospital course (e.g., lowest hematocrit, blood loss), severity of illness (e.g., Sequ

79 enous iron in hemodialysis patients within 4 hematocrit categories.

80 e-spot extraction method is less affected by hematocrit-caused errors, but it requires calibration of

81 Although we confirmed that low pre-operative hematocrit contributes to increased transfusions, we did

82 The primary end point was both hematocrit control through week 32 and at least a 35% re

83 Hematocrit control was achieved in 60% of patients recei

84 n J Index was used to determine the specific hematocrit cutoff point to define anemia in the neonatal

85 tive mortality for every percentage point of hematocrit decrease from the normal range.

86 Therefore, elevated blood viscosity and hematocrit deserve attention as emerging risk factors fo

87 lood urea nitrogen level, albumin level, and hematocrit) did not increase the risk of postoperative c

88 or the first time demonstrate that increased hematocrit does not affect therapeutic effects of EPO on

89 s in higher concentrations of hemoglobin and hematocrit during the neonatal period, and increased ser

90 is hampered by several issues, of which the hematocrit effect on DBS-based quantitation remains undo

91 A trajectory modeling, based on hematocrit evolution pattern, allowed identification of

92 precursor cells, the mice developed elevated hematocrit, expanded erythroid precursors, and suppresse

93 Hematocrit experiments show that Hct can influence the a

94 he relative decrease in platelet activity as hematocrit falls shows a similar profile for simulation

95 er these were related to maternal A1C, fetal hematocrit, fetal hormonal, or metabolic axes.

96 nsport efficiency occurs at a relatively low hematocrit for SCD patients because of hyperviscosity.

97 emoglobin to 18.6%, accompanied by increased hematocrit from 23% to 34% and reticulocyte reduction fr

98 developed a method to derive the approximate hematocrit from a nonvolumetrically applied DBS based on

99 was recorded in 5 of 182 patients in the low-hematocrit group (2.7%) and 18 of 183 patients in the hi

100 up (2.7%) and 18 of 183 patients in the high-hematocrit group (9.8%) (hazard ratio in the high-hemato

101 it group, as compared with 10.9% in the high-hematocrit group (hazard ratio, 2.69; 95% CI, 1.19 to 6.

102 ive treatment (target hematocrit, <45%) (low-hematocrit group) or less intensive treatment (target he

103 eatment (target hematocrit, 45 to 50%) (high-hematocrit group).

104 ocrit group (9.8%) (hazard ratio in the high-hematocrit group, 3.91; 95% confidence interval [CI], 1.

105 osis occurred in 4.4% of patients in the low-hematocrit group, as compared with 10.9% in the high-hem

106 2, and 2 patients, respectively, in the low-hematocrit group, as compared with 2, 1, and 5 patients,

107 1, and 5 patients, respectively, in the high-hematocrit group.

108 or transfusion among patients with baseline hematocrit > or =28%.

109 %), moderate (hematocrit, 21-30%), and mild (hematocrit, > 30%) anemia in restrictive transfusion pro

110 At 6 months, hematocrit had increased more in the altitude group (5.1

111 68, 95% confidence interval: 1.53, 1.84) and hematocrit (hazard ratio = 1.63, 95% confidence interval

112 ion after hemolysis can be used to determine hematocrit (Hct) (volume of red cells per unit volume of

113 effect of RBC membrane permeability (P(m)), hematocrit (Hct) and NO-Hb reaction rate constants on NO

114 option resistance due to factors such as the hematocrit (Hct) effects and the established preference

115 Hematocrit (Hct) is one of the most critical issues asso

116 s, it is associated with several issues, the hematocrit (Hct) issue being the most widely discussed c

117 In addition, the impact of blood hematocrit (Hct) on accurate quantification of the studi

118 sting of two exercise training phases at two hematocrit (Hct) values: 30% (anemic) and 42% (physiolog

119 28 [lead SNP rs1050828; P < 1E - 13 for Hgb, hematocrit (Hct), MCV, RBC count and red cell distributi

120 (RBC) count, hemoglobin concentration (HGB), hematocrit (HCT), mean corpuscular hemoglobin (MCH), MCH

121 ts, including hemoglobin concentration (Hb), hematocrit (Hct), mean corpuscular volume (MCV), mean co

122 Hematocrit (HCT)-based assay bias (composed of area and

123 overcoming microsample collection issues and hematocrit (HCT)-related bias would facilitate more wide

124 A (rs1800961, MAF = 2.4%, p < 3 x 10(-8) for hematocrit [HCT] and HGB).

125 Blood count, hematocrit, hemoglobin concentration and mean erythrocyt

126 c iron, inducing a dose-dependent decline in hematocrit, hemoglobin, serum iron, and transferrin satu

127 n, suggested by similar body weight, BP, and hematocrit; however, plasma renin concentrations were mo

128 creases the concentrations of hemoglobin and hematocrit, improves mean systemic blood pressure, urine

129 crit in healthy mice, we measured effects of hematocrit in 2 in vivo clot formation models.

130 Using an experimental model of elevated hematocrit in healthy mice, we measured effects of hemat

131 e IIA ligand trap, increasing hemoglobin and hematocrit in pharmacologic models, in healthy volunteer

132 nd impeded the microvascular decrease of the hematocrit in the saline and pentastarch group.

133 The blood hematocrit increased 10% at 2weeks, with no further chan

134 d from 4,830 to 1,115 mg/dL (P < .0001), and hematocrit increased from 29.8% to 38.2% (P = .0002) at

135 lagen at arterial shear rates, elevating the hematocrit increased the rate of platelet deposition and

136 In vitro, increasing the hematocrit increased thrombin generation in the absence

137 h included marked increase in hemoglobin and hematocrit, increased red blood cells, leukocytosis, thr

138 Mean hemoglobin and hematocrit increases after 90 d were greater for interve

139 imulations of whole blood predicted elevated hematocrit increases the frequency and duration of inter

140 rowth from 6 to 12 mo of age; 2) hemoglobin, hematocrit, iron [serum ferritin (SF)], and zinc status

141 ocoagulant properties in vitro, and elevated hematocrit is associated with reduced bleeding and incre

142 still unclear which parameter (hemoglobin or hematocrit) is the most reliable for demonstrating incre

143 albumin, having fallen in the past 6-months, hematocrit, Katz Score (function), and Charlson Index (c

144 y 27% of transfusions were associated with a hematocrit less than 21%.

145 ortality rates were highest in patients with hematocrit less than 30% (mortality, 2.1%) and lowest fo

146 that used larger ESA doses in patients with hematocrit less than 30% had lower mortality rates than

147 stered iron more frequently to patients with hematocrit less than 33% also had lower mortality rates

148 on was found in the subgroup with the lowest hematocrit level (26 [interquartile range, 24-28]) (haza

149 ion thresholds, described as a hemoglobin or hematocrit level below which RBCs were transfused.

150 m levels before and after RBCs lysis and the hematocrit level determined from the sodium electrode me

151 antly higher in neonates with a preoperative hematocrit level less than 40%; being 7.5% (95% CI, 1%-1

152 A preoperative hematocrit level of less than 40% was the optimal cutoff

153 Anemia defined as hematocrit level of less than 40%.

154 A postprocedure decrease in the hematocrit level of more than 13% was seen only in the s

155 el, 7.9 g/dL (normal range, 13.5-18.0 g/dL); hematocrit level, 23.2% (0.23) (normal range, 40.0%-54.0

156 tigations, such as hemogram, glucose levels, hematocrit level, arterial pH, methanol levels, potassiu

157 Hematocrit level, thyroid stimulating hormone level, aut

158 raction (ECV) was derived accounting for the hematocrit level.

159 V was calculated with input of the patient's hematocrit level.

160 er major determinants of blood viscosity are hematocrit, level of inflammatory proteins and temperatu

161 ial operative blood loss or low preoperative hematocrit levels (<24%).

162 ell as hemoglobin concentration (P = 0.002), hematocrit levels (P = 9.5 x 10(-7)) and WBC count (P =

163 (12.9 versus 15.9 thousand units/wk) but had hematocrit levels 1.1 points higher (35.7% versus 34.6%)

164 0%) vs 1.4% (95% CI, 0%-4%) for preoperative hematocrit levels 40%, or greater.

165 e also quantified the influence of different hematocrit levels and assessed the correlation of simult

166 day imprecision of quality controls at three hematocrit levels and at the lower and upper limit of qu

167 , and survival in AKI models without raising hematocrit levels and BP as substantially as EPO.

168 KI on CKD animals, with smaller increases in hematocrit levels and similarly improved survival.

169 In more recent years, patients had higher hematocrit levels before upper GI bleeding episodes and

170 mortality risks for those with preoperative hematocrit levels between 30% and 35.9% and <500 mL of b

171 ortality risks in patients with preoperative hematocrit levels between 30% to 35.9% (odds ratio 1.29,

172 oss (odds ratio: 0.35, 95% CI: 0.22-0.56 for hematocrit levels between 30%-35.9% and 0.78, 95% CI: 0.

173 Maintenance of normal hematocrit levels in Phd(2/3)hKO mice was accomplished b

174 Adiponectin and hematocrit levels increased more and fasting glucose, ur

175 isk reductions in patients with preoperative hematocrit levels of <24% (odds ratio: 0.60, 95% CI: 0.4

176 with mortality reductions for patients with hematocrit levels of 24% or greater, and conferred incre

177 en 30%-35.9% and 0.78, 95% CI: 0.62-0.97 for hematocrit levels of 36% or greater).

178 me variations of less than 2% were seen with hematocrit levels ranging from 20% to 71%.

179 In Phd(1/2/3)hKO mice, hematocrit levels reached 82.4%, accompanied by severe v

180 exogenous erythropoietin but achieve higher hematocrit levels than those living at a lower altitude.

181 re model, Phd(2/3)hKO mice maintained normal hematocrit levels throughout the 8-week time course, whe

182 RBCs) travel into side branches at different hematocrit levels, and it is even possible that all RBCs

183 yed increased malaria parasitemia, decreased hematocrit levels, and suppressed malaria-specific antib

184 e overall mortality rate was lower at higher hematocrit levels, elevated mortality risk was associate

185 iated with decreased mortality risk at lower hematocrit levels, in which mortality rates are the high

186 efined as an increase in both hemoglobin and hematocrit levels, then further dichotomized into early

187 Hematocrit levels, vascular organization, and liver lipi

188 raits, we analyzed hemoglobin concentration, hematocrit levels, white blood cell (WBC) counts and pla

189 l and platelet counts but low hemoglobin and hematocrit levels.

190 n substantially increased erythropoietin and hematocrit levels.

191 l, with smaller increases in systolic BP and hematocrit levels.

192 ficantly reduces splenomegaly and normalizes hematocrit levels.

193 iphase flows that is effective even for high hematocrit levels.

194 alytes (insulin, leptin, adiponectin, IGF-I, hematocrit, lipids, C-reactive protein, and interleukin-

195 ium <130 mmol/L (OR, 1.8; 95% CI, 1.02-3.1), hematocrit <30% (OR, 2.0; 95% CI, 1.3-3.2), pleural effu

196 The primary and secondary outcomes were HUS (hematocrit <30% with smear evidence of hemolysis, platel

197 ts with an acute myocardial infarction and a hematocrit <30%).

198 We previously found that anemia (hematocrit <34%) produces systematic error in glucometer

199 to assess the impact of preoperative anemia (hematocrit <39%) on postoperative 30-day mortality and a

200 azard ratio [HR]: 1.31), lower pre-operative hematocrit (</=31%) (HR: 1.31), ischemic etiology (HR: 1

201 time of first anemia (hemoglobin<10 gm/dL or hematocrit<30%) or first leukopenia (white blood cell [W

202 RBC transfusion among patients with severe (hematocrit, < 21%), moderate (hematocrit, 21-30%), and m

203 eive either more intensive treatment (target hematocrit, <45%) (low-hematocrit group) or less intensi

204 Maintaining a normal hematocrit may reduce arterial thrombosis risk in humans

205 difference, 2.0 [95% CI, 1.3-2.7] g/dL) and hematocrit (mean difference, 4.5% [95% CI, 1.5%-7.4%]) w

206 elet volume were significantly higher, while hematocrit, mean cell volume, and platelet counts were s

207 Hemoglobin, hematocrit, mean corpuscular volume (MCV) and prevalence

208 ardium pre- and post-gadolinium contrast and hematocrit measurement.

209 nducible factor-1alpha activation (increased hematocrit), not exacerbated further by chronic hypoxia.

210 ciated with an increased risk for mortality (hematocrit of 20% to <24%: 7.3%; 24% to <27%: 3.7%; and

211 ociated with lower mortality, for those with hematocrit of 20% to 24% (odds ratio, 0.28; 95% CI, 0.13

212 For a tube hematocrit of 25% and a spherical protrusion with a diam

213 ignificantly higher mortality for those with hematocrit of 27% to 30% (odds ratio, 3.21; 95% CI, 1.85

214 60, 95% CI: 0.41-0.87), and in patients with hematocrit of 30% or greater when there is substantial (

215 (mortality, 2.1%) and lowest for those with hematocrit of 36% or higher (mortality, 0.7%).

216 th increased mortality risk in patients with hematocrit of 36% or higher.

217 structive method which allows to predict the hematocrit of a DBS based on its hemoglobin content, mea

218 ith polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strate

219 herical particles, and tested the effects of hematocrit on particle local accessibility to flow area

220 Interestingly, the effects of hematocrit on specific circulation area was opposite for

221 association analyses of hematological trait, hematocrit, on 521 Korean family samples.

222 of a DBS suffices to derive its approximate hematocrit, one of the most important variables in DBS a

223 ular degenerative pathology without altering hematocrit or exacerbating neovascularization.

224 00/mm(3); 95% CI, 1.07-1.38), and decreasing hematocrit (OR, 0.87 per %; 95% CI, 0.79-0.96) were asso

225 providing iron (thus further increasing the hematocrit) or reducing erythropoiesis-dependent iron co

226 splay these same differences in parasitemia, hematocrit, or antibody responses between the two groups

227 omized mice, without changes in body weight, hematocrit, or extracellular fluid volume.

228 hitecture, vessel density, cardiac function, hematocrit, or other relevant peptidases.

229 associated with changes in gill morphology, hematocrit, or relative ventricular mass.

230 (P < .001); larger CRAE was related to lower hematocrit (P = .002).

231 covery (P = 0.002), decreasing elevations in hematocrit (P = 0.02), and increasing serum ferritin (P

232 le control-fed pigs had significantly higher hematocrit (p = 0.027), indicating continuing dehydratio

233 0.001), peripheral resistance (P=0.014), and hematocrit (P<0.001).

234 sheep, HRP reduced heart rate (P<0.001) and hematocrit (P=0.019) compared with time-matched control

235 significantly reduced the red blood cell and hematocrit parameters but increased the platelet counts

236 s to increased hemoglobin concentrations and hematocrit percentages and to a lower anemia prevalence

237 ars in raising hemoglobin concentrations and hematocrit percentages in anemic (hemoglobin concentrati

238 om baseline in hemoglobin concentrations and hematocrit percentages.

239 e, other aspects of vital organ support (eg, hematocrit, pH strategy), or cardiac anatomy.

240 re particles travel 1 cm downstream and that hematocrit plays a role in the degree of margination.

241 iabetes, estimated whole blood viscosity and hematocrit predicted incident type 2 diabetes mellitus i

242 puncture included mortality, vascular leak, hematocrit, quantification of a panel of serum cytokines

243 ith less than 5% volume variation across the hematocrit range of 20-70% with low tip-to-tip variabili

244 Compared with controls, mice with elevated hematocrit (RBC(HIGH)) formed thrombi at a faster rate a

245 disrupted for HIF-2alpha demonstrated lower hematocrit, RBCs, and Hb compared with wild-type mice.

246 erior to standard therapy in controlling the hematocrit, reducing the spleen volume, and improving sy

247 ieving ELN response (complete or partial) or hematocrit response did not result in better survival or

248 670 to 1590 mg/dL (P < .001), whereas median hematocrit rose from 33.0% to 37.6% (P = .004) at best r

249 flow velocity (intracranial pressure, PaCO2, hematocrit, sedation, fever,and impaired autoregulation

250 Body weight, hematocrit, serum biochemistry, and plasma concentration

251 ver the length scale of O(1 cm), with higher hematocrit showing faster margination.

252 ive abnormalities in RBCs, including altered hematocrit, sickle cell disease, thalassemia, hemolytic

253 model, CYT387 normalized white cell counts, hematocrit, spleen size, and restored physiologic levels

254 tures of MF, including leukocytosis, reduced hematocrit, splenomegaly, and increased bone marrow reti

255 f thrombosis in PV is secured by phlebotomy (hematocrit target <45%) and in both PV and ET by low-

256 h and major thrombosis than did those with a hematocrit target of 45 to 50%.

257 atients with polycythemia vera, those with a hematocrit target of less than 45% had a significantly l

258 , core temperature on CPB, pre- and post-CPB hematocrit, the preoperative use of beta-blockers or ang

259 ence suggests that a restrictive hemoglobin, hematocrit threshold or both for transfusion decreases t

260 d phagocytose human erythrocytes causing the hematocrit to fall to 2.5% of the original value.

261 Reducing hematocrit to normal levels in tubular Vegfa-deficient m

262 s established for viscosity as a function of hematocrits to predict a rise and fall in viscosity duri

263 liver iron, but little effect on hemoglobin, hematocrit, transferrin saturation, or plasma iron.

264 CD, because they can easily be measured in a hematocrit tube.

265 assess because humans and mice with elevated hematocrit typically have coexisting pathologies.

266 ow in physiologic-sized tubes at physiologic hematocrit under controlled oxygenation conditions, whil

267 not meet the defined elevated hemoglobin or hematocrit value (>18.5 g/dL and 60% in men and >16.5 g/

268 ior to establishment of HUS and (2) a higher hematocrit value at presentation.

269 A hematocrit value greater than 23% as a measure of hydrat

270 h values in the Hif-p4h-2(gt/gt) mice and in hematocrit value in the Hif-p4h-3(-/-) mice than in the

271 culated based on the percentage reduction in hematocrit value of the aspirate in relation to the pati

272 (0-30 days old) with a recorded preoperative hematocrit value were included.

273 not meet the WHO criterion for an increased hematocrit value.

274 These forces increase significantly as hematocrit values approach 25% and decrease significantl

275 infusion volume over a 6h period and higher hematocrit values compared to the ICSI model.

276 ght of the higher dietary folate intakes and hematocrit values in children without IBD.

277 4497 administration increased hemoglobin and hematocrit values similarly in the P4h-tm(-/-) and wild-

278 ce nevertheless had increased hemoglobin and hematocrit values without any FG-4497 administration, al

279 is falsely low, compared to traditional spun hematocrit values, because of an increased level of sodi

280 Median hematocrit was 0.41 L/L (0.36-0.44 L/L) at admission and

281 ean middle cerebral artery flow velocity and hematocrit was also found in boys aged 10 to 16.9 yrs.

282 postoperative blood transfusion, lower nadir hematocrit was associated with an increased risk for mor

283 potential confounders considered, only lower hematocrit was associated with high mean middle cerebral

284 A decrease in hematocrit was seen at a late interval (34-59 wk after t

285 pace perfusion (laser Doppler flowmetry) and hematocrit were analyzed.

286 Mean oxygen saturation, heart rate and hematocrit were not significantly different in G6PD defi

287 itant with slight decrease of hemoglobin and hematocrit were registered.

288 Body mass index, serum lipid levels, and hematocrit were strong phenotypic correlates of interind

289 Pretransfusion and final hematocrits were similar (P > 0.68).

290 erythropoietin was insufficient to increase hematocrit, whereas seven consecutive daily doses signif

291 for treatment of TBI significantly increase hematocrit, which may affect the efficacy of EPO therapy

292 dle cerebral artery flow velocity except for hematocrit, which was lower (25 +/- 4%; range = 21-30%)

293 ardial infarction, congestive heart failure, hematocrit, white blood cell count, mean corpuscular vol

294 an increase in red blood cells, hemoglobin, hematocrit, white blood cells, platelets, and splenomega

295 sting with the blood cell traits hemoglobin, hematocrit, white blood count, and platelet count.

296 ar events is reduced by sustained control of hematocrit with phlebotomies (low-risk patients) and/or

297 ocytes (MNLs) from diluted human blood (1-2% hematocrit) with high efficiency (>80%).

298 changes in its oxygenation, osmolarity, and hematocrit within physiologic norms, assessment of CTCs

299 .2% and 1.2%, respectively, in patients with hematocrit within the normal range (P < 0.0001).

300 was to investigate whether normalization of hematocrit would affect EPO efficacy for treatment of TB